

Cencora, Inc. (COR)

NYSE; shops; SIC 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries; CIK 0001140859

Cencora, Inc. COR; shops					
Grade	B	 second fifth of 258 graded peers percentile 35.0; sampling error 2.9 points; lower is stronger			
Rank	91 of 258				
Profitability	B/C	percentile 41.5			
Solvency	C/D	percentile 58.0			
Growth and financing	B	percentile 33.6			
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025				
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	over \$2.67B assets total assets \$76.6B				
Standard universe	inside revenue above \$1M and assets above \$10M				
Warnings	none active not computable: distress				
Inputs computable	11 of 14				
Graded from	filings received through Nov 25, 2025 318 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026				
Last close	\$321.30 2026-10-08; market equity \$61.3B				
Price used in grade	None				

B, the elk
second fifth of its sector; letters are fifths of the 258 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: B/C from Nov 21, 2024, B from Apr 21, 2025, B/C from Nov 21, 2025

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Nov 25, 2025

of this Annual Report on Form 10-K, the industries in which we operate are highly competitive. Our pharmaceutical distribution businesses not only compete with other pharmaceutical distributors, but also with manufacturers who sell directly to customers, chain drugstores who manage their own warehousing, specialty distributors, and packaging and healthcare technology companies.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 41.5						
Gross profitability		15.0%	42.6%	85.5	242	2025-09-30
Return on invested capital		54.4%	10.9%	8.4	84	2025-09-30
Accruals ratio		(3.2%)	(4.9%)	71.7	287	2025-09-30
Gross margin stability, five years		0.1 pts	1.2 pts	0.5	219	2025-09-30
Solvency, sleeve percentile 58.0						
Twelve-month failure probability		not computable	0.04%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	1.92			one or more required annual facts are missing
Net debt to EBITDA		0.90x	1.84x	37.4	100	2025-09-30
Interest coverage		not computable	2.26x			one or more required annual facts are missing
Current ratio		0.90x	1.37x	78.6	295	2025-09-30
Growth and financing, sleeve percentile 33.6						
Revenue growth, three-year compound		10.4%	1.5%	15.7	269	2025-09-30
Free cash flow growth, three-year compound		13.3%	5.6%	34.9	147	2025-09-30
Reinvestment rate		32.6%	7.3%	36.4	152	2025-09-30
Asset growth, three years		10.6%	3.4%	17.3	272	2025-09-30
Net share issuance, one year		0.4%	(0.6%)	63.8	211	2025-10-31

Among 258 peers

shops; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
86	Pool Corp. (POOL)	33.1	B	
87	Burlington Stores, Inc. (BURL)	33.5	B	
88	Weyco Group Inc. (WEYS)	33.9	B	
89	Flanigans Enterprises Inc. (BDL)	34.2	B	late filer, fortress balance sheet
90	Live Ventures Inc. (LIVE)	34.6	B	
91	Cencora, Inc. (COR) <	35.0	B	
92	Alta Equipment Group Inc. (ALTG)	35.6	B	
93	Alta Equipment Group Inc. (ALTG-PA)	35.6	B	

94	Reborn Coffee, Inc. (REBN)	36.2	B	dilution, late filer, fortress balance sheet
95	Avnet Inc. (AVT)	36.6	B	
96	Dollar General Corp. (DG)	37.0	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	4.3%	(0.1%)	57
Distance from 52-week high	(14.2%)	(24.1%)	66
EBIT to enterprise value	3.7%	5.3%	32
Free cash flow yield	5.2%	4.2%	58
Book value to price	0.05	0.36	16
Sales to price	5.24	1.75	83
Composite equity issuance, five years	(17.9%)	(16.7%)	45
Relative strength against the sector, log excess return	0.07	0.02	57

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-09-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$2.8B
Operating cash flow, four quarters	\$4.8B
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$365.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$11.5B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
2	assets	us-gaap:Assets	\$76.6B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
3	operating income	us-gaap:OperatingIncomeLoss	\$2.6B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$2.3B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$690.5M	2025-09-30	2025-11-25	10-K	0001140859-25-000131
6	total debt	us-gaap:LongTermDebt	\$7.7B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
7	book equity	us-gaap:StockholdersEquity	\$1.5B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$4.4B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
9	total debt	us-gaap:LongTermDebt	\$4.4B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
10	book equity	us-gaap:StockholdersEquity	\$645.9M	2024-09-30	2025-11-25	10-K	0001140859-25-000131
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.1B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
12	net income	us-gaap:NetIncomeLoss	\$1.6B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.9B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
14	assets	us-gaap:Assets	\$67.1B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
15	revenue	us-gaap:Revenues	\$321.3B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
16	gross profit	us-gaap:GrossProfit	\$9.9B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
17	revenue	us-gaap:Revenues	\$294.0B	2024-09-30	2025-11-25	10-K	0001140859-25-000131

18	gross profit	us-gaap:GrossProfit	\$9.0B	2023-09-30	2025-11-25	10-K	0001140859-25-000131
19	revenue	us-gaap:Revenues	\$262.2B	2023-09-30	2025-11-25	10-K	0001140859-25-000131
20	gross profit	us-gaap:GrossProfit	\$8.3B	2022-09-30	2024-11-26	10-K	0001140859-24-000177
21	revenue	us-gaap:Revenues	\$238.6B	2022-09-30	2024-11-26	10-K	0001140859-24-000177
22	gross profit	us-gaap:GrossProfit	\$6.9B	2021-09-30	2023-11-21	10-K	0001140859-23-000197
23	revenue	us-gaap:Revenues	\$214.0B	2021-09-30	2023-11-21	10-K	0001140859-23-000197
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.1B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
25	current assets	us-gaap:AssetsCurrent	\$52.2B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
26	current liabilities	us-gaap:LiabilitiesCurrent	\$57.8B	2025-09-30	2025-11-25	10-K	0001140859-25-000131
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$668.0M	2025-09-30	2025-11-25	10-K	0001140859-25-000131
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.5B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$487.2M	2024-09-30	2025-11-25	10-K	0001140859-25-000131
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.9B	2023-09-30	2025-11-25	10-K	0001140859-25-000131
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$458.4M	2023-09-30	2025-11-25	10-K	0001140859-25-000131
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.7B	2022-09-30	2024-11-26	10-K	0001140859-24-000177
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$496.3M	2022-09-30	2024-11-26	10-K	0001140859-24-000177
34	current assets	us-gaap:AssetsCurrent	\$47.7B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
35	current liabilities	us-gaap:LiabilitiesCurrent	\$54.3B	2024-09-30	2025-11-25	10-K	0001140859-25-000131
36	assets	us-gaap:Assets	\$62.6B	2023-09-30	2024-11-26	10-K	0001140859-24-000177
37	assets	us-gaap:Assets	\$56.6B	2022-09-30	2023-11-21	10-K	0001140859-23-000197
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	193,993,444	2025-10-31	2025-11-25	10-K	0001140859-25-000131
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	193,280,140	2024-10-31	2024-11-26	10-K	0001140859-24-000177